We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KVACU
76
DELISTED
Keen Vision Acquisition Corp Units
KVACU
$793K 0.15%
75,000
– –
APLS
77
DELISTED
Apellis Pharmaceuticals
APLS
$792K 0.15%
20,650
-5,050
-20% -$229K
SLN
78
Silence Therapeutics
SLN
$526M
$766K 0.14%
40,290
+200
+0.5% +$4.25K
KPRX icon
79
Kiora Pharmaceuticals
KPRX
$11.1M
$725K 0.14%
172,596
+50,374
+41% +$235K
SRPT icon
80
Sarepta Therapeutics
SRPT
$1.73B
$703K 0.13%
4,450
-26,655
-86% -$3.42M
CTMX icon
81
CytomX Therapeutics
CTMX
$727M
$698K 0.13%
572,170
+417,170
+269% +$830K
CATX icon
82
Perspective Therapeutics
CATX
$341M
$698K 0.13%
69,985
+2,312
+3% +$33.4K
CLYM
83
Climb Bio
CLYM
$716M
$695K 0.13%
+97,695
New +$650K
XAIR icon
84
Beyond Air
XAIR
$4.4M
$658K 0.12%
3,063
+51
+2% +$25.4K
KZR
85
DELISTED
Kezar Life Sciences
KZR
$652K 0.12%
108,650
+84,988
+359% +$646K
VXRT
86
DELISTED
Vaxart
VXRT
$631K 0.12%
+945,568
New +$785K
CTVA icon
87
Corteva
CTVA
$53.3B
$615K 0.12%
11,400
-26,000
-70% -$1.43M
ARYD
88
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$614K 0.12%
53,527
+12,597
+31% +$143K
IWM icon
89
PUT
iShares Russell 2000 ETF
IWM
$83.1B
$609K 0.11%
+3,000
New +$606K
AKRO
90
DELISTED
Akero Therapeutics
AKRO
$598K 0.11%
25,507
+23,700
+1,312% +$507K
MRNA icon
91
CALL
Moderna
MRNA
$23B
$594K 0.11%
+5,000
New +$633K
TSHA icon
92
Taysha Gene Therapies
TSHA
$1.8B
$562K 0.11%
250,800
+207,300
+477% +$603K
ATNM icon
93
Actinium Pharmaceuticals
ATNM
$24.2M
$556K 0.11%
75,133
-24,867
-25% -$205K
TMTC
94
DELISTED
TMT Acquisition Corp Ordinary Shares
TMTC
$549K 0.1%
50,000
– –
CRBP icon
95
Corbus Pharmaceuticals
CRBP
$174M
$543K 0.1%
12,000
-4,000
-25% -$168K
RYTM icon
96
Rhythm Pharmaceuticals
RYTM
$7.47B
$534K 0.1%
13,000
+600
+5% +$23.9K
ARDX icon
97
Ardelyx
ARDX
$1.24B
$519K 0.1%
+70,000
New +$492K
YEAR icon
98
AB Ultra Short Income ETF
YEAR
$1.51B
$505K 0.1%
10,000
– –
PULS icon
99
PGIM Ultra Short Bond ETF
PULS
$18.3B
$497K 0.09%
10,000
– –
STVN icon
100
Stevanato
STVN
$5.48B
$495K 0.09%
27,000
+11,500
+74% +$268K
2 3
4
5 6

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.